Presentation is loading. Please wait.

Presentation is loading. Please wait.

30 years as a biotechnological company to research to develop to produce to commercialize Biotechnological process for HEALTH.

Similar presentations


Presentation on theme: "30 years as a biotechnological company to research to develop to produce to commercialize Biotechnological process for HEALTH."— Presentation transcript:

1

2

3 30 years as a biotechnological company to research to develop to produce to commercialize Biotechnological process for HEALTH

4

5

6 strong bet in RESEARCH 19812012 Projects Patents Publicactions Implantation of new technologies

7 19811983 NO COMMERCIAL ACTIVITY

8 1981198319841991 1 COMMERCIAL PRODUCT  Equipments,  Diversification,  R&D Contracts FINANCIAL CRASH OF THE MAIN SHAREHOLDER 1992 NO COMMERCIAL ACTIVITY

9 1981198319841991 1994 NEW STRATEG COMMERCIAL RANGE DEVELOPMENT ? CAPITAL 1 COMMERCIAL PRODUCT  Equipments,  Diversification,  R&D Contracts NO COMMERCIAL ACTIVITY

10 19942011 COMMERCIAL ACTIVITY 40 Mill de Pts 5,1 Mill de € 100% PRIVATE

11 Private capital 100 %

12 Tools for reaching our objectives

13 Toos for reaching our objectives technologies know how human team

14

15 Human team 42 people universitary degree (biologists, veterinarian, biochemist) Technicians Assistants External Service Administration 20 12 5 1 4

16

17 Immunoassays PCR Mab development Protein expression systems Transcriptonic Phage-display thecnologies

18 Immunoassays PCR Mab development Protein expression systems Transcriptómic Phage-display

19 Immunoassayss based on the specific binding between antígen and antibody ELISAs Immunochromatografic test

20

21 Immunoassays PCR Mab development Protein expression systems Transcriptómic Phage-display

22 PCR techniques based on the replication of specific sequences of nucleic acids x2x2 x2x2 x2x2 x2x2 x2x2 x2x2 x2x2 x2x2 x2x2

23

24

25 PCR

26 Immunoassays PCR Mab development Protein expression systems Transcriptómic Phage-display

27 Monoclonal Antibodies Development Originate biological systems able to produce an antibody (immunoglobulin) specific for a single antigenic determinant TRADITIONAL METHODNEW TECHNOLOGY + development production PHAGE DISPLAY

28 Immunoassays PCR MAb development Proteins expression system Transcriptomic Phage-display

29 Proteins expression system Use of the cellular system to synthesize peptides or proteins of interest

30 Proteins expression system Use of the cellular system to synthesize peptides or proteins of interest

31 Proteins expression system PROCARIOTIC SYSTEM EUCARIOTIC SYSTEM

32 Immunoassays PCR MAb development Proteins expression system Transcriptomic Phage-display

33 Transcriptomic Evaluation of the expression level of particular genes by studding the mRNA present in the cells. Arrays Bioinformatics analysis

34 Immunoassays PCR MAb development Proteins expression system Transcriptomic Phage-display

35 Allows knowing and selecting sequences codifying for biologically “useful” peptides or proteins. Uses the ability of some phages to expose at their capside proteins or peptides codified by genes artificially inserted in their genome. PHAGE

36 Phage-display PHAGO A gene from a library of genes

37 Phage-display PHAGO each phage receives a different and unique gene Each phage will expose at its capside one kind of exogenous protein or peptide

38 PHAGE Phage-display In every phage, there is a coexistence between the gene and the protein codified by this gene.

39 PHAGE Phage-display If we are able to select the phages through the activity of the protein they express …. … we have selected the gene which codify for this protein!

40 know how

41 79 Publications 62 Patents 36 Proyects

42 Our OBJETIVE is still the same

43

44 OBJETIVE research development production commercialization Biotechnology procedures applied to HEALTH animal plants human food

45 OBJETIVE research development production commercialization Biotechnology procedures applied to HEALTH animal plants human food

46 R esearch + D evelopment R&D

47 DUAL Strategy SHORT-TERM Diagnostic Procedures Short periods for registration Using industrial structure = very quickly in the market COMMERCIAL ACTIVITY LONG-TERM Vaccines and therapeutics Long periods for registration Require a bigger industrial structure to be in the market. PATENTS LICENSE

48 R & D Short Term R&D, today on market Actual product catalogue:

49 Veterinarian diagnosis 8 animal species 61 pathologies 105 references R & D Short Term R&D, today on market Actual product catalogue:

50 R & D Short Term R&D, today on market Actual product catalogue:

51 R & D Short Term R&D, today on market Actual product catalogue: Plant diseases diagnosis Food safety Human diagnosis

52 R & D Short Term R&D, today on market Actual product catalogue:

53 R & D Short Term R&D, today on market Actual product catalogue: Technologies Elisas Inmunochromatografy PCRs

54 R & D LongTerm R&D, actual ID projects

55 R & D Long Term R&D: actual R&D projects We are a small company, but we have surrounded ourselves by great institutions in many of our projects: ID-DLO (NL) SVIV (DK) Inst. PASTEUR (FR) OXFORD Univ. (UK)

56 R & D Long Term R&D: actual R&D projects

57 R & D Long Term R&D: actual R&D projects VI Programa Marco Immune Response to respiratory virus infections and vaccination in elderly.

58 New tools and approaches to control Porcine Reproductive and Respiratory Syndrome in the EU and ASIA (PRSSCon)” Development of multivalent vaccines for BTV, EHDV and AHSV (ORVIVAC) R & D Long Term R&D: actual R&D projects VII Programa Marco Evaluating and controlling the risk of African Swine Fever in the EU (ASFRisk) Strategies for the eradication of Bovine Tuberculosis. (TB-Step)

59 R & D Long Term R&D: actual R&D projects

60 R & D Long Term R&D: actual R&D projects Research and Development of new technologies for therapeutic applications and diagnosis for Cancer. 2006-2010. Cenit porject

61 R & D Long Term R&D: actual R&D projects Biomarkers searching for colon, lung, ovary and melanoma cancers and development of tests for diagnosis/prognosis

62 R & D Long Term R&D: actual R&D projects Our partners in the project:

63 R & D Long Term R&D: actual R&D projects Technologies and phases of the project in which we participated: Levels of genic expression analysis for biomarkers selection Specific antibodies development to the selected biomarkers MONOCLONAL ANTIBODIES TRANSCRIPTONICS ASSAYS DEVELOPMENT Desing and completion of detection tests (ELISA DAS, IC)

64 M anufacturing & S ales M & S

65 manufacturing under rigorous QC rules and controls

66 M & S Facilities Reagents preparation 01

67 M & S Facilities Coating plates 02

68 M & S Facilities Coating plates 02

69 M & S Facilities Coating plates 02

70 M & S Facilities Coating plates 02

71 M & S Facilities Packaging and storage 03

72 M & S Facilities Packaging of kits 04

73 M & S Products distribution

74 M & S Products distribution Large distribution net world wide 3956 distributorspresents in countries

75 M & S Products distribution NARVAC 2 CL TSENG LIFE STAR MICRONIC AGROVET SCIENTIFIC LINE MEGAPHARMA TIN HANG

76 M & S Products distribution NOACK BIOGNOSIS PLATERO QEFII DIACHEL PRIONICS AGROLABO TRASCO INGENASA

77

78 still growing...


Download ppt "30 years as a biotechnological company to research to develop to produce to commercialize Biotechnological process for HEALTH."

Similar presentations


Ads by Google